(Q34529488)

2 August 2017

title

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease (English)

1 reference

2 August 2017

0 references

1 reference

Willem van Eden

1 reference

2 August 2017

Peter Thomas

1 reference

2 August 2017

Kamran Ghoreschi

1 reference

2 August 2017

Susanne Breit

1 reference

2 August 2017

Martin Dugas

1 reference

2 August 2017

Reinhard Mailhammer

1 reference

2 August 2017

Ruurd van der Zee

1 reference

2 August 2017

Tilo Biedermann

1 reference

2 August 2017

Jörg Prinz

1 reference

2 August 2017

Matthias Mack

1 reference

2 August 2017

Ulrich Mrowietz

1 reference

2 August 2017

Enno Christophers

1 reference

2 August 2017

Detlef Schlöndorff

1 reference

2 August 2017

Gerd Plewig

1 reference

2 August 2017

Christian A Sander

1 reference

2 August 2017

Martin Röcken

1 reference

2 August 2017

language of work or name

English

0 references

publication date

2 December 2002

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

40-46

1 reference

Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris

2 August 2017

cites work

1 reference

7 January 2021

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

1 reference

7 January 2021

Inflammatory skin diseases, T cells, and immune surveillance

1 reference

7 January 2021

Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines

1 reference

7 January 2021

Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis

1 reference

7 January 2021

Cyclosporine consensus conference: with emphasis on the treatment of psoriasis

1 reference

7 January 2021

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

1 reference

7 January 2021

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

7 January 2021

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

7 January 2021

Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

1 reference

7 January 2021

Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings.

1 reference

7 January 2021

Interleukin-10 and the interleukin-10 receptor

1 reference

7 January 2021

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

1 reference

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

7 January 2021

New treatments for psoriasis

1 reference

7 January 2021

Tolerance and autoimmunity

1 reference

7 January 2021

IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease

1 reference

7 January 2021

Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells

1 reference

7 January 2021

Functional diversity of helper T lymphocytes

1 reference

7 January 2021

Lymphocyte responses and cytokines

1 reference

7 January 2021

Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo

1 reference

7 January 2021

IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice

1 reference

7 January 2021

Lymphokine production by human T cells in disease states

1 reference

7 January 2021

Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo

1 reference

7 January 2021

Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level

1 reference

7 January 2021

A strict requirement of interleukin-4 for interleukin-4 induction in antigen-stimulated human memory T cells

1 reference

7 January 2021

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

1 reference

7 January 2021

CCR5 is characteristic of Th1 lymphocytes

1 reference

7 January 2021

Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2.

1 reference

7 January 2021

Psoralen bath plus UV-A therapy. Possibilities and limitations

1 reference

7 January 2021

Interleukin 20: discovery, receptor identification, and role in epidermal function

1 reference

7 January 2021

Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint

1 reference

7 January 2021

The IL-4 receptor: signaling mechanisms and biologic functions

1 reference

7 January 2021

Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo

1 reference

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

7 January 2021

IL-4 Is a Mediator of IL-12p70 Induction by Human Th2 Cells: Reversal of Polarized Th2 Phenotype by Dendritic Cells

1 reference

7 January 2021

The interleukin-10 family of cytokines

1 reference

7 January 2021

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

1 reference

7 January 2021

Safety evaluation of recombinant human interleukin-4. II. Clinical studies.

1 reference

7 January 2021

Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection

1 reference

7 January 2021

Identifiers

DOI

10.1038/NM804

1 reference

2 August 2017

1 reference